These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 36573513)
41. Dapagliflozin for heart failure: is it a class effect? Raj GM; Wyawahare M Future Cardiol; 2021 Mar; 17(2):355-361. PubMed ID: 32755319 [TBL] [Abstract][Full Text] [Related]
42. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys. Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249 [TBL] [Abstract][Full Text] [Related]
43. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Evans M; Morgan AR; Davies S; Beba H; Strain WD Age Ageing; 2022 Oct; 51(10):. PubMed ID: 36201329 [TBL] [Abstract][Full Text] [Related]
44. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Packer M Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851 [TBL] [Abstract][Full Text] [Related]
45. Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. Shah KS; Fang JC Annu Rev Pharmacol Toxicol; 2022 Jan; 62():109-120. PubMed ID: 34516288 [TBL] [Abstract][Full Text] [Related]
46. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology. Mai Z; Li H; Chen G; Chen E; Liu L; Lun Z; Lai W; Zhou C; Yu S; Liu J; Chen S; Chen J; Liu Y Cardiovasc Drugs Ther; 2022 Aug; 36(4):713-726. PubMed ID: 34028657 [TBL] [Abstract][Full Text] [Related]
47. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349 [TBL] [Abstract][Full Text] [Related]
48. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients. Kashiwagi A; Araki S; Maegawa H J Diabetes Investig; 2021 Jan; 12(1):6-20. PubMed ID: 32563214 [TBL] [Abstract][Full Text] [Related]
49. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Garcia-Ropero A; Badimon JJ; Santos-Gallego CG Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454 [TBL] [Abstract][Full Text] [Related]
50. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis. Liu T; Li R; Wang X; Gao X; Zhang X Med Clin (Barc); 2022 Jul; 159(2):65-72. PubMed ID: 34872768 [TBL] [Abstract][Full Text] [Related]
51. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821 [TBL] [Abstract][Full Text] [Related]
52. Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: Current evidence and future perspectives. Jensen J; Omar M; Kistorp C; Gustafsson F; Køber L; Møller JE; Schou M Basic Clin Pharmacol Toxicol; 2022 Jul; 131(1):5-17. PubMed ID: 35510595 [TBL] [Abstract][Full Text] [Related]